Sign in

CIK 0000748592 · Non-accelerated filer<br>Smaller reporting company

Ernexa Therapeutics Inc.

Sign in to watch
Ticker
ERNA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
311103425
Phone
(617) 798-6700
Business address
1035 CAMBRIDGE STREET, SUITE 18A, CAMBRIDGE, MA, 02141
Former names
Eterna Therapeutics Inc., Brooklyn ImmunoTherapeutics, Inc., NTN BUZZTIME INC, NTN COMMUNICATIONS INC

Securities

  • ERNA Common Stock Nasdaq
  • ERNAW Warrants Nasdaq
  1. 4/A Insider Changes in Ownership
  2. 4/A Open-market buy Director bought 5,455 shares at an average $0.29 ($1,558)
  3. 3/A Insider 3/A
  4. 4 Open-market buy EVP of Product and Technology bought 10,000 shares at $0.47 ($4,700)
  5. 4 Open-market buy Director bought 10,000 shares at $0.42 ($4,200)
  6. 4/A Open-market buy Director bought 9,900 shares at $0.40 ($3,960)
  7. 4 Open-market buy Director bought 88,200 shares at an average $0.40 ($35,279)
  8. 4 Open-market buy Director bought 1,300 shares at $0.41 ($533)
  9. 4 Open-market buy Director bought 2,700 shares at $0.36 ($972)
  10. 4 Open-market buy Director bought 10,000 shares at $0.40 ($4,000)
  11. D Other Notice of Sales of Unregistered Securities
  12. 4 Open-market buy Director bought 20,000 shares at $0.39 ($7,800)
  13. 4 Open-market buy 10% owner bought 50,000 shares at $0.39 ($19,405)
  14. 8-K Event Material agreement · Acquisition or sale completed · Unregistered share sale
  15. 10-Q Report Quarterly Report
  16. 8-K Event Exhibits
  17. 3 Insider Initial Statement of Ownership
  18. 3 Insider Initial Statement of Ownership
  19. 4 Open-market buy 10% owner bought 75,000 shares at an average $0.35 ($26,610)
  20. DEF 14A Proxy Proxy Statement

Page 54 of 77 · 1,525 filings